Viatris VTRS
NASDAQ VTRS
$16.50 -0.11 (-0.66%)
As of: Sep 9, 2026 · 3:59 PM EDT

Viatris (VTRS) Net Income Growth (3y) (2022 - 2026)

Analysis

Viatris (VTRS) Net Income Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Teva Pharmaceutical Industries 42.84 Bn 39.19 Bn 2.15 Bn 14.04%
2 Viatris 19.13 Bn 18.24 Bn 1.46 Bn -34.81%
3 Dr Reddys Laboratories 9.91 Bn 9.74 Bn 396.53 Mn -35.35%
4 Amneal Pharmaceuticals 5.51 Bn 5.38 Bn 334.51 Mn 32.86%
5 Bausch Health Companies 2.30 Bn 464.50 Mn 2.10 Bn 112.75%
6 Alvotech 1.50 Bn 1.36 Bn 2.56 Mn -
7 Ani Pharmaceuticals 1.49 Bn 1.13 Bn 165.89 Mn 58.10%
8 Amphastar Pharmaceuticals 1.00 Bn 714.13 Mn 93.47 Mn 4.72%
9 Fennec Pharmaceuticals 402.10 Mn 360.85 Mn 17.15 Mn 33.27%
10 RedHill Biopharma 178.35 Mn 178.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -34.81%
Mar 31, 2026 -7.75%
Dec 31, 2025 -32.69%
Sep 30, 2025 -33.17%
Jun 30, 2025 -26.30%
Mar 31, 2025 -112.68%
Dec 31, 2024 -25.10%
Sep 30, 2024 -32.74%
Jun 30, 2024 -5.34%
Mar 31, 2024 28.26%
Dec 31, 2023 5.80%
Sep 30, 2023 58.24%
Jun 30, 2023 565.94%
Mar 31, 2023 121.06%
Dec 31, 2022 291.90%